27/08/2023
Mesenchymal Stem Cells: An Excellent Candidate for the Treatment of Diabetes Mellitus
Nội dung bài viết
Hindawi
International Journal of Endocrinology
Volume 2021, Article ID 9938658, 11 pages
https://doi.org/10.1155/2021/9938658
Review Article
International Journal of Endocrinology
Volume 2021, Article ID 9938658, 11 pages
https://doi.org/10.1155/2021/9938658
Review Article
Mesenchymal Stem Cells: An Excellent Candidate for the Treatment of Diabetes Mellitus
Qiulan Huang , Yanting Huang , and Jianping Liu
Department of Endocrinology, e Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Correspondence should be addressed to Jianping Liu; liujpnfm@163.com
Received 10 March 2021; Accepted 19 May 2021; Published 28 May 2021
Academic Editor: Andrea Tura
Copyright © 2021 Qiulan Huang et al. +is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Mesenchymal stem cells (MSCs) are adult stem cells (ASCs) known for repairing damaged cells, exerting anti-inflammatory responses and producing immunoregulatory effects that can be significantly induced into insulin-producing cells (IPCs), providing an inexhaustible supply of functional β cells for cell replacement therapy and disease modeling for diabetes. MSC therapy may be the most promising strategy for diabetes mellitus because of these significant merits. In this paper, we focused on MSC therapy for diabetes.
Department of Endocrinology, e Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Correspondence should be addressed to Jianping Liu; liujpnfm@163.com
Received 10 March 2021; Accepted 19 May 2021; Published 28 May 2021
Academic Editor: Andrea Tura
Copyright © 2021 Qiulan Huang et al. +is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Mesenchymal stem cells (MSCs) are adult stem cells (ASCs) known for repairing damaged cells, exerting anti-inflammatory responses and producing immunoregulatory effects that can be significantly induced into insulin-producing cells (IPCs), providing an inexhaustible supply of functional β cells for cell replacement therapy and disease modeling for diabetes. MSC therapy may be the most promising strategy for diabetes mellitus because of these significant merits. In this paper, we focused on MSC therapy for diabetes.
